The Role of ACKR3 in Breast, Lung, and Brain Cancer.
Journal
Molecular pharmacology
ISSN: 1521-0111
Titre abrégé: Mol Pharmacol
Pays: United States
ID NLM: 0035623
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
received:
21
11
2018
accepted:
30
01
2019
pubmed:
13
2
2019
medline:
4
3
2020
entrez:
13
2
2019
Statut:
ppublish
Résumé
Recent reports regarding the significance of chemokine receptors in disease have put a spotlight on atypical chemokine receptor 3 (ACKR3). This atypical chemokine receptor is overexpressed in numerous cancer types and has been involved in the modulation of tumor cell proliferation and migration, tumor angiogenesis, or resistance to drugs, thus contributing to cancer progression and metastasis occurrence. Here, we focus on the clinical significance and potential mechanisms underlying the pathologic role of ACKR3 in breast, lung, and brain cancer and discuss its possible relevance as a prognostic factor and potential therapeutic target in these contexts.
Identifiants
pubmed: 30745320
pii: mol.118.115279
doi: 10.1124/mol.118.115279
doi:
Substances chimiques
ACKR3 protein, human
0
Receptors, CXCR
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
819-825Informations de copyright
Copyright © 2019 by The American Society for Pharmacology and Experimental Therapeutics.